Colorectal Cancer Prevention (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (05/12/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Overview

Added text to state that a recent report compared the COX-2 inhibitor celecoxib with the nonselective nonsteroidals naproxen and ibuprofen in individuals with severe arthritis and showed that serious cardiovascular events were not less common for those taking the nonselective nonsteroidals; however, the study did not assess the comparative safety of lower doses or the safety of the COX-2 inhibitor rofecoxib (cited Nissen et al. reference 33).

Description of the Evidence

Revised text to state that about 4.4% of Americans are expected to develop colorectal cancer within their lifetimes (cited Howlader et al. as reference 5).

This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section

Description of the Evidence

Next section >

About This PDQ Summary